Citation: Ey. Kim et al., Anti-HIV type 1 activity of 3 '-fluoro-3 '-deoxythymidine for several different multidrug-resistant mutants, AIDS RES H, 17(5), 2001, pp. 401-407
Authors:
Kundu-Raychaudhuri, S
Sevin, A
Kilgo, P
Nokta, M
Pollard, RB
Merigan, TC
Citation: S. Kundu-raychaudhuri et al., Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4(+) T cell counts of <= 500 and 200-400/mm(3) (AIDS Clinical Trials Group study 246/946), AIDS RES H, 17(15), 2001, pp. 1371-1378
Authors:
Shafer, RW
Hertogs, K
Zolopa, AR
Warford, A
Bloor, S
Betts, BJ
Merigan, TC
Harrigan, R
Larder, BA
Citation: Rw. Shafer et al., High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients, J CLIN MICR, 39(4), 2001, pp. 1522-1529
Citation: Ma. Winters et Tc. Merigan, Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs, ANTIM AG CH, 45(8), 2001, pp. 2276-2279
Authors:
Kim, EY
Winters, MA
Kagan, RM
Merigan, TC
Citation: Ey. Kim et al., Functional correlates of insertion mutations in the protease gene of humanimmunodeficiency virus type 1 isolates from patients, J VIROLOGY, 75(22), 2001, pp. 11227-11233
Authors:
Winters, MA
Baxter, JD
Mayers, DL
Wentworth, DN
Hoover, ML
Neaton, JD
Merigan, TC
Citation: Ma. Winters et al., Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens, ANTIVIR TH, 5(1), 2000, pp. 57-63
Authors:
Shapero, MH
Kundu, SK
Engleman, E
Laus, R
van Schooten, WCA
Merigan, TC
Citation: Mh. Shapero et al., In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients, CELL TRANSP, 9(3), 2000, pp. 307-317
Authors:
Gray, CM
Lawrence, J
Ranheim, EA
Vierra, M
Zupancic, M
Winters, M
Altman, J
Montoya, J
Zolopa, A
Schapiro, J
Haase, AT
Merigan, TC
Citation: Cm. Gray et al., Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activatedT cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8(+) T cells, AIDS RES H, 16(14), 2000, pp. 1357-1369
Authors:
Baxter, JD
Mayers, DL
Wentworth, DN
Neaton, JD
Hoover, ML
Winters, MA
Mannheimer, SB
Thompson, MA
Abrams, DI
Brizz, BJ
Ioannidis, JPA
Merigan, TC
Citation: Jd. Baxter et al., A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy, AIDS, 14(9), 2000, pp. F83-F93
Authors:
Winters, MA
Coolley, KL
Cheng, P
Girard, YA
Hamdan, H
Kovari, LC
Merigan, TC
Citation: Ma. Winters et al., Genotypic, phenotypic, and modeling studies of a deletion in the beta 3-beta 4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors, J VIROLOGY, 74(22), 2000, pp. 10707-10713
Authors:
Schooley, RT
Spino, C
Kuritzkes, D
Walker, BD
Valentine, FT
Hirsch, MS
Cooney, E
Friedland, G
Kundu, S
Merigan, TC
McElrath, MJ
Collier, A
Plaeger, S
Mitsuyasu, R
Kahn, J
Haslett, P
Uherova, P
deGruttola, V
Chiu, S
Zhang, B
Jones, G
Bell, D
Ketter, N
Twadell, T
Chernoff, D
Rosandich, M
Citation: Rt. Schooley et al., Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214, J INFEC DIS, 182(5), 2000, pp. 1357-1364
Authors:
Katzenstein, DA
Kundu, S
Spritzler, J
Smoller, BR
Haszlett, P
Valentine, F
Merigan, TC
Citation: Da. Katzenstein et al., Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen, J ACQ IMM D, 22(4), 1999, pp. 341-347
Citation: S. Palmer et al., Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development, AIDS, 13(6), 1999, pp. 661-667
Authors:
Schapiro, JM
Winters, MA
Lawrence, J
Merigan, TC
Citation: Jm. Schapiro et al., Clinical cross-resistance between the HIV-1 protease inhibitors saquinavirand indinavir and correlations with genotypic mutations, AIDS, 13(3), 1999, pp. 359-365
Citation: S. Palmer et al., Hydroxyurea enhances the activities of didanosine, 9-[2(phosphonylmethoxy)ethyl] adenine, and 9-[2(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates, ANTIM AG CH, 43(8), 1999, pp. 2046-2050
Authors:
Lawrence, J
Schapiro, J
Winters, M
Montoya, J
Zolopa, A
Pesano, R
Efron, B
Winslow, D
Merigan, TC
Citation: J. Lawrence et al., Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons, J INFEC DIS, 179(6), 1999, pp. 1356-1364
Authors:
Kleim, JP
Winters, M
Dunkler, A
Suarez, JR
Riess, G
Winkler, I
Balzarini, J
Oette, D
Merigan, TC
Citation: Jp. Kleim et al., Antiviral activity of the human immunodeficiency virus type 1 specific nonnucleoside reverse transcriptase inhibitor HBY097 alone and in combination with zidovudine in a phase II study, J INFEC DIS, 179(3), 1999, pp. 709-713
Authors:
Schapiro, JM
Lawrence, J
Speck, R
Winters, MA
Efron, B
Coombs, RW
Collier, AC
Merigan, TC
Citation: Jm. Schapiro et al., Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229, J INFEC DIS, 179(1), 1999, pp. 249-253
Authors:
Gray, CM
Lawrence, J
Schapiro, JM
Altman, JD
Winters, MA
Crompton, M
Loi, M
Kundu, SK
Davis, MM
Merigan, TC
Citation: Cm. Gray et al., Frequency of class I HLA-restricted anti-HIV CD8(+) T cells in individualsreceiving highly active antiretroviral therapy (HAART), J IMMUNOL, 162(3), 1999, pp. 1780-1788
Authors:
Valantine, HA
Gao, SZ
Menon, SG
Renlund, DG
Hunt, SA
Oyer, P
Stinson, EB
Brown, BW
Merigan, TC
Schroeder, JS
Citation: Ha. Valantine et al., Impact of prophylactic immediate posttransplant ganciclovir on developmentof transplant atherosclerosis - A post hoc analysis of a randomized, placebo-controlled study, CIRCULATION, 100(1), 1999, pp. 61-66
Authors:
Zolopa, AR
Shafer, RW
Warford, A
Montoya, JG
Hsu, P
Katzenstein, D
Merigan, TC
Efron, B
Citation: Ar. Zolopa et al., HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed, ANN INT MED, 131(11), 1999, pp. 813
Authors:
Kundu, SK
Dupuis, M
Sette, A
Celis, E
Dorner, F
Eibl, M
Merigan, TC
Citation: Sk. Kundu et al., Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization, AIDS RES H, 14(18), 1998, pp. 1669-1678
Authors:
Shafer, RW
Winters, MA
Palmer, S
Merigan, TC
Citation: Rw. Shafer et al., Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients (vol 128, pg 906, 1998), ANN INT MED, 129(12), 1998, pp. 1083-1083